GlaxoSmithKline Pharmaceuticals Limited

Equities

GLAXO

INE159A01016

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:50 2024-04-19 am EDT 5-day change 1st Jan Change
1,869 INR -1.08% Intraday chart for GlaxoSmithKline Pharmaceuticals Limited -1.38% -1.50%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GlaxoSmithKline Pharmaceuticals Limited Receives Orders from Government Authorities CI
Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14% MT
Glaxosmithkline Pharmaceuticals Limited Appoints Aparajita Mukherjee Rajput, Technology Lead CI
GlaxoSmithKline Pharmaceuticals Sees Sharp Decline in Fiscal Q3 Consolidated Net Profit MT
GSK India arm's Q3 profit falls on government price cap RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
GlaxoSmithKline Pharmaceuticals Limited Announces Resignation of Sunder Ramachandran as Head of Commercial Excellence, Effective 12 January 2024 CI
GlaxoSmithKline Pharmaceuticals Limited Announces Resignation of Abhinav Kashyap as Pharma Technology Lead CI
GSK's India unit posts Q2 profit rise on strong vaccine demand RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
GlaxoSmithKline Pharmaceuticals Limited Appoints Omkar Parnandiwar as Head of Omnichannel, Effective November 1, 2023 CI
Glaxosmithkline Pharmaceuticals Records Rise in Fiscal Q1 Consolidated Net Profit MT
India's GlaxoSmithKline Pharma posts rise in Q1 profit on steady vaccine business RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Samsung Biologics unveils $920 mln manufacturing deals for Pfizer RE
A son died, his parents tried to sue. How U.S. courts protect Big Pharma RE
Abbott's India arm posts 9.5% rise in fourth-quarter profit RE
GlaxoSmithKline Pharmaceuticals's Net Profit Slumps in Fiscal Q4 MT
India's GlaxoSmithKline Pharma's pre-tax profit falls on govt pricing caps RE
GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
GlaxoSmithKline Pharmaceuticals Limited Proposes Final Dividend for the Year Ended March 31, 2023 CI
Pfizer's India unit posts 3% rise in Q4 profit RE
Transcript : GlaxoSmithKline Pharmaceuticals Limited - Shareholder/Analyst Call
GlaxoSmithKline Pharmaceuticals Fiscal Q3 Consolidated Net Profit Grows MT
GSK's India unit posts 9% rise in Q3 profit as input costs slump RE
Chart GlaxoSmithKline Pharmaceuticals Limited
More charts
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
1,869 INR
Average target price
2,141 INR
Spread / Average Target
+14.58%
Consensus
  1. Stock Market
  2. Equities
  3. GLAXO Stock
  4. News GlaxoSmithKline Pharmaceuticals Limited
  5. GlaxoSmithKline Pharmaceuticals : to Sell Karnataka Manufacturing Business in India to Hetero Labs